Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen

Clinical Cancer Research

Volumn 15, Issue 18, 2009, Pages 5811-5819

  Mullenders, Jasper ^a   Von Der Saal, Wolfgang ^b   Van Dongen, Miranda M W ^a   Reiff, Ulrike ^b   Van Willigen, Rogier ^a   Beijersbergen, Roderick L ^a   Tiefenthaler, Georg ^b   Klein, Christian ^b   Bernards, René ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DDB1 PROTEIN; ETOPOSIDE; NOCODAZOLE; PACLITAXEL; R 3200; RBX1 PROTEIN; SHORT HAIRPIN RNA; SULFONAMIDE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE ARREST; COLON ADENOCARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE REPRESSION; GENE SILENCING; GENETIC RESISTANCE; GENETIC SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PRIORITY JOURNAL; RNA INTERFERENCE; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CELL CYCLE; CELL PROLIFERATION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; RNA INTERFERENCE; SULFONAMIDES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 70349448673     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0261     Document Type: Article

References (25)

1. Corbett TH, White K, Polin L, et al. Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169. Invest New Drugs 2003;21:33-45. (Pubitemid 36628483)
2. Lobb KL, Hipskind PA, Aikins JA, et al. Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem 2004;47:5367-5380
3. Mader MM, Shih C, Considine E, et al. Acyl sulfonamide anti-proliferatives. Part 2. Activity of heterocyclic sulfonamide derivatives. Bioorg Med Chem Lett 2005;15:617-620
4. Haritunians T, Gueller S, O'Kelly J, Ilaria R, Jr., Koeffler HP. Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells. Oncol Rep 2008;20:1237-1242
5. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-856 (Pubitemid 41746029)
6. Sawyers CL. The cancer biomarker problem. Nature 2008;452:548-552
7. Bartz SR, Zhang Z, Burchard J, et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 2006;26:9377-9386 (Pubitemid 44904431)
8. Whitehurst AW, Bodemann BO, Cardenas J, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007;446:815-819 (Pubitemid 46582032)
9. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402. (Pubitemid 47539306)
10. Bernards R, Brummelkamp TR, Beijersbergen RL. shRNA libraries and their use in cancer genetics. Nat Methods 2006;3:701-706
11. Berns K, Hijmans EM, Mullenders J, et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004;428:431-437 (Pubitemid 38419689)
12. Cui W, Taub DD, Gardner K. qPrimerDepot: a primer database for quantitative real time PCR. Nucleic Acids Res 2007;35:D805-9. (Pubitemid 46056313)
13. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-592 (Pubitemid 34800230)
14. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58. (Pubitemid 37328807)
15. Brummelkamp TR, Fabius AW, Mullenders J, et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2006;2:202-206
16. Wertz IE, O'Rourke KM, Zhang Z, et al. Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science 2004;303:1371-1374 (Pubitemid 38269430)
17. Schlabach MR, Luo J, Solimini NL, et al. Cancer proliferation gene discovery through functional genomics. Science 2008;319:620-624 (Pubitemid 351197064)
18. Tan M, Davis SW, Saunders TL, Zhu Y, Sun Y. RBX1/ROC1 disruption results in early embryonic lethality due to proliferation failure, partially rescued by simultaneous loss of p27. Proc Natl Acad Sci U S A 2009;106:6203-6208
19. Groisman R, Polanowska J, Kuraoka I, et al. The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell 2003;113:357-367 (Pubitemid 36556117)
20. Hu J, McCall CM, Ohta T, Xiong Y. Targeted ubiquitination of CDT1 by the DDB1-4A-ROC1 ligase in response to DNA damage. Nat Cell Biol 2004;6:1003-1009 (Pubitemid 39359854)
21. Higa LA, Mihaylov IS, Banks DP, Zheng J, Zhang H. Radiation-mediated proteolysis of CDT1 by CUL4-1 and CSN complexes constitutes a new checkpoint. Nat Cell Biol 2003;5:1008-1015 (Pubitemid 37406915)
22. Wang H, Zhai L, Xu J, et al. Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin ligase facilitates cellular response to DNA damage. Mol Cell 2006;22:383-394 (Pubitemid 44308132)
23. Nishitani H, Lygerou Z, Nishimoto T, Nurse P. The Cdt1 protein is required to license DNA for replication in fission yeast. Nature 2000;404:625-628 (Pubitemid 30205063)
24. Chu G, Chang E. Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA. Science 1988;242:564-567 (Pubitemid 18263195)
25. Kapetanaki MG, Guerrero-Santoro J, Bisi DC, Hsieh CL, Rapic-Otrin V, Levine AS. The DDB1-4ADDB2 ubiquitin ligase is deficient in xeroderma pigmentosum group E and targets histone H2A at UV-damaged DNA sites. Proc Natl Acad Sci U S A 2006;103:2588-2593 (Pubitemid 43306593)